Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 907048 | ISIN: FR0000035370 | Ticker-Symbol: 1DJ
Frankfurt
06.06.25 | 15:29
28,300 Euro
+0,35 % +0,100
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BASTIDE LE CONFORT MEDICAL SA Chart 1 Jahr
5-Tage-Chart
BASTIDE LE CONFORT MEDICAL SA 5-Tage-Chart
RealtimeGeldBriefZeit
28,60028,70017:11

Aktuelle News zur BASTIDE LE CONFORT MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoBASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium199Caissargues, June 5, 2025 Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for...
► Artikel lesen
BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln
MiBASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK211Caissargues, June 4, 2025 After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region...
► Artikel lesen
15.05.BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed308Caissargues, May 15, 2025 In € millions 2023-2024 published 2023-2024* Adjusted 2024-2025 published Change First-quarter revenue 127.9 122.7 133.8 +9.1% Second-quarter...
► Artikel lesen
19.03.BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1%457Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025...
► Artikel lesen
13.02.BASTIDE: Organic growth of 8.4% in first-half 2024 2025: Home healthcare services up 10.2% and Return to growth in the Homecare business / 2024-2025 targets confirmed374Caissargues, February 13, 2025 In € millions 2023-2024 published 2023-2024* Adjusted 2024-2025 published Change First-quarter revenue 127.9 122.7 133.8 +9.1% Second-quarter...
► Artikel lesen
08.01.BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment / Sale of French stomatherapy subsidiary CICA PLUS307Caissargues, January 8, 2025 - Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British...
► Artikel lesen
14.11.24BASTIDE: Highly dynamic organic growth in Q1 2024-25 at 9.0%: 10.9% growth in home healthcare services and rebound in the homecare business, up 6.0% / Disposal of Swiss commercial business finalized and 2024-2025 targets confirmed394Caissargues, November 14, 2024 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2024-2025, ending September 30, 2024. In...
► Artikel lesen
04.11.24BASTIDE: 2024-2025 financial calendar300Caissargues, November 4, 2024 Events Dates* 2024-2025 Q1 Revenue Thursday November 14, 2024 2024-2025 H1 Revenue Thursday February 13, 2025 2024-2025 H1 Results Wednesday...
► Artikel lesen
23.10.24BASTIDE: 2023-2024 annual results: Solid growth in revenue and recurring operating margin of 8.5%, exceeding the target / improved profitability and a focus on reducing debt in 2024-25314Caissargues, October 23, 2024 - Groupe Bastide, leading European provider of home healthcare services, announces its earnings for the 2023-2024 financial year ended 30 June 2024. The full-year...
► Artikel lesen
29.08.24BASTIDE: Annual revenue: EUR 530 million (up 8.2%) exceeding the target of EUR 520 million / Organic growth accelerated in fourth quarter 2023-2024: up 9.5% / Profitability target of 8.4% confirmed for 2023-2024321Caissargues, August 29, 2024 In € millions 2022-2023 published 2022-2023* restated 2023-2024 published Change Fourth-quarter revenue 127.9 122.2 134.5 +10.1% Annual...
► Artikel lesen
25.07.24BASTIDE: Financing resources reinforced through a new syndicated loan - Medium-term financing secured and debt maturity extended546Caissargues, July 25, 2024 Groupe Bastide announced today that it has set up a new financing contract for €375 million, including a syndicated loan and a revolving credit facility, as part of its...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1